CD19-targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome
Last Updated: Wednesday, September 20, 2023
Researchers investigated use of CD-19 directed CAR T-cell therapy for antisynthetase syndrome, which is a rare autoimmune disorder with both B-cell and T-cell involvement that is characterized by interstitial lung disease and myositis. When added to mycophenolate mofetil to co-target CD8+ T cells, CAR T-cell therapy deeply resets B-cell immunity.
Advertisement
News & Literature Highlights
